Government
Please check out the biopharma industry’s COVID-19 stories that are trending for April 6, 2021.
Sepsis is among the best-known and least effectively treated conditions in the modern world. The standard of care has failed for these infections, leaving the U.S. healthcare system with $62 billion and 270,000 deaths annually. Globally, 11 million die from sepsis each year. Effective drugs and diagnostics are available. They’re just not used.
In a statement, the company said, “Bristol Myers Squibb is in compliance with all applicable tax rules and regulations. We work with leading experts in this area and will continue to work cooperatively with the IRS to resolve this matter. Beyond that, we don’t comment on ongoing regulatory matters.”
Illumina plans to continue to pursue its acquisition of Grail Inc. despite the objection of the U.S. Federal Trade Commission.
There appears to be some evidence that the agency is cracking down in general, although there’s debate among analysts about what exactly is going on.
What has been learned about SARS-CoV-2, the virus that causes COVID-19, in only about 15 months, is truly a historical scientific achievement. And new information continues to come in.
Three days after U.S. Food and Drug Administration staff raised safety concerns over Pfizer’s and Eli Lilly’s NGF osteoarthritis drug tanezumab, an advisory panel has also posted its own objections.
The announcement by the NIAID, a part of the National Institutes of Health (NIH), is very unusual.
Change is coming to the pharmaceutical supply chain. The supply chain review ordered by President Biden virtually guarantees it with its attempts to understand and improve issues related to supply chain transparency, security and overreliance on a few suppliers in a few regions.
Although the beginning of March was fairly slow, the end of the month shows a busy schedule for PDUFA dates for the U.S. FDA. Read on to see what’s on the calendar for this week.
PRESS RELEASES